DNA microarray expression signatures are expected to provide new insights into patho-physiological pathways. Numerous variant statistical methods have been described for each step of the signal analysis. We employed five similar statistical tests on the same data set at the level of gene selection. Inter-test agreement for the identification of biological pathways in BioCarta, KEGG and Reactome was calculated using Cohen's κ-score. The identification of specific biological pathways showed only moderate agreement (0.30 < κ < 0.79) between the analysis methods used. Pathways identified by microarrays must be treated cautiously as they vary according to the statistical method used.
Introduction
DNA microarrays emerged as one of the dominant technologies in biomedical research during the past decade. A major promise of the method is thought to lie in the potential to identify genes actively involved in patho-physiological pathways 1 . Discovery of such pathways and their genetic regulation may lead to targeted efforts in drug discovery.
It has by now become clear that gene clusters ("signatures"), rather than the expression of individual genes, yield higher information contents. The ultimate aim is to move from signatures to models, that is, to analyze the data, integrate the information, and thus, gain knowledge 1 .
The information contained in the expression data is made available through a sequence of statistical analyses, which are not yet standardized. Most reports on DNA microarray data feature a very unique methodology. Often, the information on the methods used is insufficient to allow replication.
When assessing the usefulness of a technology, much attention must be given to the robustness of the knowledge gain, i.e. different observers should come to the same conclusion by using this method.
The present study addresses this point. More precisely, we ask: if one and the same set of microarray data is analyzed using different statistical tests at the same analytic step, will the same pathways be identified? (The data set and statistical methods are described in detail in Appendix A.) This was done by calculating Cohen's κ -score 2 , which allows to assess whether inter-test agreement is more than a chance product.
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In addition, we assessed the inter-test mutual agreement at different levels of analysis of the data set, namely the biological level (in terms of both gene and pathway identification) and the clinical level (case sample clustering). The comparison of these test results allows to judge the robustness of the information contents, and the independence from the possible introduction of bias through onomastically variant, but de facto redundant entries in the protein databases.
Results
Each statistical test produced a gene set of 50 genes, according to the conditions chosen. There was only partial overlap (Table 1) with not more than three genes common to all five tests. The generalized κ-score 3 was κ= -28.01.
At the analytical step of gene selection, Cohen's κ-score was low (0.15 < κ < 0.68), indicative of only "fair" to at best "substantial" agreement (Table 2) .
Following submission of the five sets of 50 genes selected by the different statistical methods to all three pathway databases as described in the methods section, some genes were found to be involved in more than one pathway described in one or more of the three databases, and in each set of selected genes, pathways were identified that involved more than one of these genes (Table 3 ). A total of 38 genes (Appendix B:
Additional Table 1 ) could not be allocated to any pathway described in any of the three databases. We used Cohen's kappa score to calculate agreement at the level of pathway identification between the five statistical methods. The κ -scores ranged from 0.30 to 5 0.79 as displayed in Table 3 , which indicates mostly "moderate", in three cases "substantial", and twice only "fair" agreement between the five test methods. Most of the higher agreement scores were seen between Golub's method and any one of the other methods.
In order to assess the consistency between gene and pathway based inter-test similarities, the matrices reported in Table 2 and Table 3 were correlated to each other by means of Pearson's correlation coefficient calculated between corresponding elements.
The correlation coefficient of r = 0.916 points to a substantial equivalence between gene and pathway information and rules out possible bias due to differences in gene assignment to different pathways as a function of the databases used.
When the inter-test concordance matrix based on the diagnosis reported by Golub et al was correlated with the corresponding gene and pathway based matrices, we saw a complete lack of concordance between biological (gene and pathway) and clinical (diagnosis) levels (r = 0.055 and r=0.916 for gene-diagnosis and pathway-diagnosis consistency). Table 4 reports the inter-test pairwise k-scores for these three levels of analysis while Figure 1 shows the mutual correlation between gene-pathway and gene-patient inter-test correlation matrices.
Discussion
DNA microarrays have much evolved over the past decade to become a dominant technology in the life sciences. The huge promise of this technology lies in its capacity to carry out high throughput analysis. As such, it is of great interest for both research in basic (patho-) physiology, as well as for screening assays towards "biomarkers" in an industrial setting. Microarrays produce vast amounts of data; analysis of this data provides information that ultimately serves to increase knowledge.
Data, information and knowledge are closely related, but separate entities. They may be defined as simple observation ("data", e.g. differential expression of signals on a microarray), data with relevance and purpose ("information" e.g. an expression signature used to classify samples) and valuable information from the human mind ("knowledge" e.g. different prognosis for AML and ALL cases classified by microarray through differential expression signals). 4 In a situation where data is commonly analyzed by variant approaches, it becomes imperious to ascertain the robustness of information gain and knowledge creation. In clinical settings, the robustness of information is commonly assessed by Cohen's κ-score.
This κ-score tests whether the inter-tester agreement is factual, or a product of chance.
We used this simple and elegant method to assess to what extent the information gain from microarray data used for pathway discovery is more than a chance product.
The overall κ-score of -28.01 is indicative of below chance agreement only: the agreement between the selected signatures is arbitrary, despite the formal similarities between the tests. This indicates that a per-chance choice of method is more likely to 7 succeed. Golub's method is on average the 'most correlated' with the other tests, giving it a 'central' position. Both at the stage of gene selection, and of pathway identification, the inter-test agreement between the five statistical tests is, on average, only "fair" for selection and "moderate" for identification. Moreover, the gene and pathway based mutual similarities between tests are highly correlated, thus showing that the same basic information is carried by gene and pathway based analyses.
The low kappa scores at the selection stage can be explained by the large "marginal imbalance" between selected genes (n=50) and unselected genes (n=6095) 5, 6 .
This, however, is not the case at the stage of pathway identification which in turn was The kappa scores for the pathway involvement show that the same data set, depending on which statistical method the researcher chooses to make use of, may provide considerably different "knowledge" gain. In other words, depending on which test is used on the same data set, different pathways are considered to be involved in the condition. Essentially the same conclusion, expressed in opposite terms, was drawn by Suarez-Farinas et al 7 , who showed that a normalized assessment of raw data from the The inter-test similarity structure arising from the case sample classification is completely independent from the gene and pathway based similarity structures ( Figure 1 and Table 2 ). This points to a relative independence of the clinical judgement from the Taken together, the analysis presented here shows that even after the critical analytic step of signal processing and normalizing, variation in analytical procedures may reduce the coherence of the conclusion.
The observations reported in the present study should serve two immediate purposes. Firstly, the findings remind both technology developers and users that only validated information becomes knowledge. In view of the low agreement scores for pathway discovery shown here, information from microarray analysis must be considered very critically and not be accepted as knowledge too easily.
Secondly, and in analogy to the technological refinements that have been put into place, our observations should encourage research into the refinement of statistical analysis methods.
On a more general level, our results substantiate the need to progressively abandon the 'single gene' or even 'pathway' level of analysis in order to look at a different level of physiological co-regulation modes.
Methods
We assessed the inter-test agreement as described by Cohen's κ-score between five statistical tests [16] [17] [18] [19] [20] used in the analysis of DNA microarray expression data 2 . The data set analyzed was from the well characterized study on acute leukemia by Golub et al.
which has a detailed methodology section that allows stepwise replication of the κ-scores are reported at the level of gene-selection and pathway identification on the "training" samples.
The matrices reporting the pairwise inter-tests κ-scores relative to the concordance were correlated at the level of gene-selection and pathway identification so 
